Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

141 results about "Adenocarcinoma of the lung" patented technology

Adenocarcinoma of the lung is the most common type of lung cancer, and like other forms of lung cancer, it is characterized by distinct cellular and molecular features. It is classified as one of several non-small cell lung cancers (NSCLC), to distinguish it from small cell lung cancer which has a different behavior and prognosis. Lung adenocarcinoma is further classified into several subtypes and variants. The signs and symptoms of this specific type of lung cancer are similar to other forms of lung cancer, and patients most commonly complain of persistent cough and shortness of breath. Adenocarcinoma is more common in patients with a history of cigarette smoking, and is the most common form of lung cancer in younger women and Asian populations. The pathophysiology of adenocarcinoma is complicated, but generally follows a histologic progression from cells found in healthy lungs to distinctly dysmorphic, or irregular, cells. There are several distinct molecular and genetic pathways that contribute to this progression. Like many lung cancers, adenocarcinoma of the lung is often advanced by the time of diagnosis. Once a lesion or tumor is identified with various imaging modalities, such as computed tomography (CT) or X-ray, a biopsy is required to confirm the diagnosis. Treatment of this lung cancer is based upon the specific subtype and the extent of spread from the primary tumor. Surgical resection, chemotherapy, radiotherapy, targeted therapy and immunotherapy are used in attempt to eradicate the cancerous cells based upon these factors.

Autoantigen biomarkers for early diagnosis of lung adenocarcinoma

Provided herein are novel panels of biomarkers for the detection and diagnosis of lung adenocarcinoma, and methods and kits for detecting these biomarkers in samples of individuals suspected of having the disease. Also provided are methods of monitoring the progression of lung adenocarcinoma and methods of monitoring the efficacy of a treatment.
Owner:FRED HUTCHINSON CANCER RES CENT +1

Dipeptide boric acid composed of carboxylic acid and alpha-amino acid as well as ester compound thereof, and preparation method and application of dipeptide boric acid and ester compound thereof

The invention belongs to the field of drug synthesis and in particular relates to a series of novel peptide boric acids as well as an ester compound or pharmaceutical salt thereof, and a preparation method and application of the peptide boric acids as well as the ester compound or pharmaceutical salt thereof in pharmacodynamics. A structure of the peptide boric acid and the ester compound or pharmaceutical salt thereof is shown in a formula I (described in the specification). The compound provided by the invention can be used for preparing a proteasome inhibitor and can further be used for treating solid tumours and blood tumours, wherein the solid tumours are selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, gastrointestinal stromal tumor, nasopharynx cancer and leukemia; and the blood tumours are selected from multiple myeloma, mantle cell lymphoma and histiocytic lymphoma.
Owner:JIANGSU CHIA TAI FENGHAI PHARMA

LncRNA biomarkers for diagnosing human lung adenocarcinoma and human colorectal cancer

The invention relates to the technical field of biology, and in particular relates to a group of LncRNA biomarkers for diagnosing human lung adenocarcinoma and human colorectal cancer, related kits and application thereof. The group of LncRNA biomarkers for diagnosing human lung adenocarcinoma and / or human colorectal cancer comprises uc001gzl.3, ENST00000434223, uc004bbl.1, ENST00000540136 and NR_034174. The LncRNA biomarkers for diagnosing the human lung adenocarcinoma and / or human colorectal cancer can be used for distinguishing human early lung adenocarcinoma and human colorectal cancer, the AUC of the biomarkers for distinguishing early lung adenocarcinoma from normally paired lung tissues can reach 0.978, and the sensitivity and the specificity are respectively 92% and 98%. The AUC of the biomarkers for diagnosing a colorectal cancer sample can reach 0.963, and the sensitivity and the specificity are respectively 94.4% and 88.9%.
Owner:SHANGHAI INST OF MICROSYSTEM & INFORMATION TECH CHINESE ACAD OF SCI

Identification of early diagnosis markers of lung adenocarcinoma based on co-expression similarity, and constructing method of risk prediction model

ActiveCN109841281ARealize automatic classification predictionRealize non-invasive diagnosisHealth-index calculationMedical automated diagnosisCorrelation analysisUnsupervised clustering
The invention belongs to the technical field of lung adenocarcinoma prediction, and specifically relates to an identification of early diagnosis markers of lung adenocarcinoma based on co-expression similarity, and a constructing method of a risk prediction model. The constructing method includes the steps of: data remodeling and grouping, data standardization, phase specific gene extraction, geneco-expression correlation analysis, unsupervised cluster analysis, specific and non-specific co-expression network analysis, functional pathway gathering, significant variation pathway identification, screening of early screening marker genes by using an REE algorithm, establishment of a classification model based on early screening risk genes, survival analysis verification, and the like. The identification of early diagnosis markers of lung adenocarcinoma based on co-expression similarity, and the constructing method of a risk prediction model can realize the early diagnosis of lung cancer,and can identify gene markers which change significantly with the progress of lung cancer at the same time.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

EML4-ALK (Echinoderm microtubule associated protein like4-anaplastic lymphoma kinase) fusion gene fluorescent quantitative PCR (polymerase chain reaction) assay kit

The invention relates to an EML4-ALK (echinoderm microtubule associated protein like4-anaplastic lymphoma kinase) fusion gene fluorescent quantitative PCR (polymerase chain reaction) assay kit, which is applicable to assay of EML4-ALK fusion gene mutation in lung adenocarcinoma. The kit comprises probes, primers and positive controls, which are specially designed for conserved sequences of 9 fusion variations of the EML4-ALK fusion gene. The kit can be used for quickly and accurately assaying 9 most common EML4-ALK fusion gene variations with high sensitivity, namely 9 fusion variations of 7 variant subtypes, which are subtype 1 (E13; A20), subtype 2 (E20; A20), subtype 3 (E6a / b; A20), subtype 4 (E14; A20), subtype 5 (E2a / b; A20), subtype 6 (E18; A20) and subtype 7 (E14; A20), so that a real-time fluorescent quantitative PCR system for assaying 9 most common EML4-ALK fusion gene variations can be established.
Owner:广州达健生物科技有限公司

Epitope of cd66c specific to lung adenocarcinoma and antibody recognizing the same

The present invention relates to epitope of CD66c specific to lung adenocarcinoma and antibody recognizing the same. The present invention relates to identifying epitope of CD66c specific to lung adenocarcinoma, antibody recognizing the same, cell lines producing the same and the applications in diagnosis, prevention and treatment of lung adenocarcinoma by using the same. The above CD66c epitope is specific to lung adenocarcinoma cells, and therefore the antibody or its fragment recognizing the epitope can be used in compositions to diagnose, treat and prevent lung adenocarcinoma cells.
Owner:KUMHO HT

Novel use of niclosamide and pharmaceutically acceptable salt thereof

The invention discloses an application of niclosamide or pharmaceutically-acceptable salts thereof in preparing anti-tumor drugs, which provides a candidate drug for tumor patients and may further improve the therapeutic effect and the prognosis to patients. The effectiveness of niclosamide or pharmaceutically-acceptable salts thereof on various tumor cells indicates that the composition may be used for treating various cancers such as cerebroma, genitourinary tumor, lymphatic system, stomach cancer, cancer of larynx, nasopharyngeal cancer, skin cancer, bone cancer, leukaemia, leukaemia, breast cancer, histiocytic lymphoma, non-small-cell lung cancer, small-cell lung cancer, lung adenocarcinoma, epidermoid cancer, pancreatic cancer, prostatic cancer, liver cancer and epithelial cell cancer.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI

Prognosis marker for lung cancer and application thereof

InactiveCN109136370AImproved prognosisConvenience prognostic survival is very correlated by markerMicrobiological testing/measurementDNA/RNA fragmentationMolecular levelCvd risk
The invention discloses a prognosis marker for the lung cancer and application thereof. The long chain non-coding RNA gene RP11-434D9.1 of the marker is quite related to the prognosis period of patients with the lung cancer, through the marker and expression for detecting the marker, lung cancer prognosis is rapidly, accurately and conveniently predicted, the grading and layering of lung cancer risks are realized according to molecular levels, and patients with different grades of risks are separated obviously. Through co-expression analysis, 238 genes related to the long chain non-coding RP1-434D9.1 are found out, through an enrichment analysis on GO and KEGG pathways of the 238 genes, the molecular functions of the long-chain non-coding RP1-434D9.1 are found out, and important biologicalexperiment clues are provided for improving prognosis molecular diagnosis of the patients with the lung cancer and related medicine targets.
Owner:广州表观生物科技有限公司 +1

MiRNA marker in serum exosome related to early diagnosis of lung adenocarcinoma and application

The invention discloses a miRNA marker in a serum exosome related to early diagnosis of lung adenocarcinoma and application. The marker is selected from hsa-miR-4516, hsa-miR-342-3p, hsa-miR-199a-3p, hsa-miR-150-5p, hsa-miR-140-3p, hsa-miR-18a-5p, hsa-miR-222-3p, hsa-miR-27a-3p, hsa-miR-29a-3p, hsa-miR-221-3p, hsa-miR-500a-3p, hsa-miR-6126 and hsa-miR-6715a-3p. The marker can effectively separate early lung adenocarcinoma cases from healthy people. The marker and probes thereof can be used for preparing a lung adenocarcinoma early diagnosis kit. The marker has an assisting effect on early diagnosis of lung adenocarcinoma.
Owner:FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIV

Compound having anticancer activity and preparation method

The invention provides a compound having anticancer activity, which is obtained by cooperation of Norabieta cantharidin and platinum (IV) and modification of a piperazine derivative. The compound is characterized in that a Norabieta cantharidin piperazine derivative ligand is introduced, thereby cytotoxicity of a platinum (IV) compound is reduced, and high antineoplastic activity is provided. The result of the cytotoxicity experiments shows that the provided platinum (IV) compound has less destruction to normal mice fibroblast L929, but has good killing effect to cancer cells such as human breast cancer MCF-7 cell, human cervical carcinoma HeLa cell and human lung adenocarcinoma A549 cell, so that the compound having anticancer activity is capable of reducing the system toxicity and having equal anticancer activity with cisplatin. The compound having anticancer activity has good killing effect by aiming at cisplatin resistance human lung adenocarcinoma A549 / DDP cell. Therefore, the toxicity is reduced, the cisplatin resistance can be reversed, and anticancer effect of the platinum medicines can be increased.
Owner:CHANGCHUN INST OF APPLIED CHEMISTRY - CHINESE ACAD OF SCI

Application of HoxC11 as biological marker for preparing lung adenocarcinoma pre-diagnostic reagent

The invention discloses an HoxC11 gene or HoxC11 gene which can be used for preparing a lung adenocarcinoma pre-diagnostic reagent and a kit and preparing lung adenocarcinoma pre-diagnostic prognosis evaluation reagents or treatment drugs. Reverse transcription is performed after RNA is extracted from a normal lung tissue sample of lung adenocarcinoma, expression of HoxC11 is detected through a real-time fluorescence quantification method, and a result shows that HoxC11 can be highly expressed in lung adenocarcinoma tissue. It is promoted that HoxC11 can be used as a lung adenocarcinoma pre-diagnostic molecular marker. The powerful molecular biology tool is provided for lung adenocarcinoma auxiliary diagnosis and prognosis prediction, and the profound clinic significance and significant application and popularization prospects are achieved.
Owner:CENT SOUTH UNIV

Marker for diagnosing and treating lung adenocarcinoma

The invention discloses a marker for diagnosing and treating lung adenocarcinoma. The PLD5 gene is highly expressed in lung adenocarcinoma tissues, the inhibition of the expression of the PLD5 gene can promote the apoptosis of lung adenocarcinoma cells. The expression level of the PLD5 gene in the lung tissues can be detected to sensitively and specifically diagnose lung adenocarcinoma. The invention also provides a treatment means for lung adenocarcinoma.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD

Markers and diagnostic reagents for the diagnosis or prognosis of lung cancer

The present invention relates to markers and diagnostic reagents for the diagnosis or prognosis of lung cancer. The present invention discloses for the first time that DDX56 is significantly increasedin patients with early disease progression (= 12 months) after treatment of two major subtypes of small cell lung cancer (lung squamous cell carcinoma, lung adenocarcinoma), and that the increased expression of DDX56 significantly affects the overall survival of the patients. Therefore, DDX56 can be used as a diagnostic marker for early recurrence of lung squamous cell carcinoma or lung adenocarcinoma.
Owner:CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI +1

Composition related to lung adenocarcinoma metastasis and application thereof

The invention relates to a composition related to lung adenocarcinoma metastasis and application thereof and particularly relates to novel application of the composition composed of one or more of the mir-193a, mir-3942, mir-767, mir-193b and mir-550a-1 and / or matures miRNA for diagnosing the lung adenocarcinoma metastasis. By performing sequencing analysis on the lung adenocarcinoma metastatic group and the non-metastatic group, a reserved drone gene is chosen to perform molecular biology verification. The result shows that the miRNA provided by the invention is closely related to the lung adenocarcinoma metastasis. The composition can be used for clinical diagnosis and preventive detection and has good practical application value.
Owner:BEIJING MEDINTELL BIOMED CO LTD

Fructus terminaliae billericae extract with anti-cancer effect, and preparation method of effective part of fructus terminaliae billericae extract

The invention relates an anticancer active part of fructus terminaliae billericae, and a preparation method of the anticancer active part. The invention comprises extraction of the part containing active components, study of a process for enriching by adopting macroporous absorption resin, identification of the active components in the active part, and use of the active part in in-vivo or in-vitroinhibition of liver cancer HepG2, lung cancer A549, lung adenocarcinoma NCI-H1703, gastric cancer BGC823, osteosarcoma cell MG-63, colorectal cancer HCT116, breast cancer MCF-7, neuroblastoma cells shsy5y, kidney cancer ACHN, normal liver cells L02, human breast ductal carcinoma cells ZR75-1, human colorectal adenocarcinoma cells Colo-205, human breast ductal carcinoma cells BT-474, human breastcancer cells T-47D, human cervical cancer cell line HeLa, liver cancer cells H22, and the like. The enrichment method applying the macroporous absorption resin to the anti-cancer active part of the fructus terminaliae billericae is simple in process, safe, non-toxic and low in production cost, and can be used for industrial production, thus having a great economic benefit and higher generalizationperformance.
Owner:BEIJING UNIV OF CHINESE MEDICINE

Application of biomarker as target to diagnosis and treatment of lung adenocarcinoma

The invention discloses application of a biomarker as a target to the diagnosis and the treatment of lung adenocarcinoma. Particularly, the biomarker is CLINT1. The worldwide incidence rate of the lung adenocarcinoma continuously increases; an effective biomarker is needed to diagnose and / or treat the lung adenocarcinoma. The application is proven through an experiment; the expression, in a patient suffered from the lung adenocarcinoma, of the CLINT1 is up-regulated; the multiplication and the invasion of a lung adenocarcinoma cell can be inhibited by decreasing the expression of a CLINT1 gene. Prompted, the CLINT1 disclosed by the invention can be used as a marker for the early diagnosis of the lung adenocarcinoma; meanwhile, the gene can be also used as a potential drug target spot for treating the lung adenocarcinoma; the foundation is provided for the accurate medical treatment of the lung adenocarcinoma.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD

FUSION GENE OF Kif5b GENE AND Ret GENE, AND METHOD FOR DETERMINING EFFECTIVENESS OF CANCER TREATMENT TARGETING FUSION GENE

In order to identify a gene that can serve as an indicator for predicting the effectiveness of a drug treatment of cancer and to provide a novel method for predicting the effectiveness of a drug treatment targeting said gene, lung adenocarcinomas were subjected to whole-transcriptome sequencing. As a result, in-frame fusion transcripts between the KIF5B gene and the RET gene were identified. The KIF5B-RET gene fusions were detected in 6 out of 319 (2%) LADC specimens from Japanese individuals and 1 out of 80 (1%) LADC specimens from U.S.A. individuals. None of the seven subjects revealed known activating mutations such as EGFR, KRAS or ALK oncogenes; thus, said gene fusions were found to be responsible mutations (driver mutations) for oncogenesis. Since said gene fusions are considered to induce constitutive activation of RET tyrosine kinase protein, it was found that treatments with RET tyrosine kinase inhibitors are effective in patients with detection of said gene fusions.
Owner:NAT CANCER CENT

Traditional Chinese medicinal composition for treating lung cancer and liver cancer

The invention discloses a traditional Chinese medicinal composition for treating lung cancer and liver cancer. The composition consists of rhizoma paridis yunnanensis extract, rhizoma curcumae longae extract and white paeony root extract according to a mass ratio of 1:(15-25):(5-15). Experiments prove that the traditional Chinese medicinal composition can obviously inhibit lung cancer cell lines such as LA795 and hepatoma cell lines such as Hep-B3 from growing, the half maximal inhibitory concentrations (IC50) of the lung cancer cell lines and the hepatoma cell lines can respectively reach below 20 micrograms / milliliter; tests on mouse models bearing lung adenocarcinoma and liver cancer tumors show that the lung adenocarcinoma and liver cancer inhibition rates are respectively above 50%, and the spleen index and liver index of mice are increased; and compared with raw medicinal materials which are separately applied, the medicinal composition has high anti-lung cancer and anti-liver cancer activities, an exact effect and a good inhibition effect on lung cancer and liver cancer.
Owner:TIANJIN UNIV

Lung adenocarcinoma individuation prognosis evaluation method based on polygene expression characteristic spectrum

ActiveCN108363907APrecise Survival StatusReflect the state of existenceHealth-index calculationHybridisationLinear correlationCvd risk
The invention discloses a lung adenocarcinoma individuation prognosis evaluation method based on a polygene expression characteristic spectrum. The method comprises the following steps that a lung adenocarcinoma prognosis risk gene list and weight are acquired; a prognosis evaluation model is established by using a tumor tissue transcriptome and survival data of a patient with lung adenocarcinoma;a risk score of the patient is calculated according to a gene expression spectrum of the tumor tissue of the patient with lung adenocarcinoma; the annual survival probability of the patient is calculated according to the risk score of the patient. According to the method, the annual survival probability of the patient with lung adenocarcinoma and the actual annual survival probability are highlyidentical, the linear correlation R2 is equal to 0.994, and the P value is equal to 2.86E-43. It is proved that the method has high prediction accuracy, and the state is highly identical to the actualsurvival state. Meanwhile, for each patient with lung adenocarcinoma, the method can provide a specific survival probability curve of the patient.
Owner:KUNMING INST OF ZOOLOGY CHINESE ACAD OF SCI

Application of lncRNA (long no-coding RNA) in diagnosis and tretament of lung adenocarcinoma

The invention discloses an application of lncRNA (long no-coding RNA) which is LINC01983 in diagnosis and tretament of lung adenocarcinoma. Significant up-regulation of expression of the LINC01983 inlung adenocarcinoma is found for the first time, and large-sample QPCR experiments further prove that the LINC01983 can be applied to clinical diagnosis of the lung adenocarcinoma as a potential molecular target. The invention also discloses the LINC01983 related to proliferation, migration and invasion of lung adenocarcinoma cells, which indicates that the LINC01983 can be applied to clinical diagnosis of the lung adenocarcinoma as the potential molecular target.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD

Mark used for prediction of prognosis of lung adenocarcinoma

The invention discloses a mark used for prediction of prognosis of a lung adenocarcinoma. The mark is composed of OPN3, GALNT2, FAM83A AND KYUN, and a mathematical model for prediction of prognosis ofthe lung adenocarcinoma is established based on the four indexes of OPN3, GALNT2, FAM83A AND KYUN, wherein the expression formula of the mathematical model is P=0.0004A+0.0042B+0.0055C+0.0077D, in the formula, P is a risk coefficient, A is the expression quantity of OPN3, B is the expression quantity of GALANT2, C is the expression quantity of FAM83A, and D is the expression quantity of KYNU. When P is higher than 0.216, it is defined to have a high risk, and otherwise it is defined to have a low risk. The prediction for AUC of the prognosis of the lung adenocarcinoma reaches 0.71 through themodel, when cut-off is 0.216, the sensitiveness of predicting a three-year overall life cycle of a patient with the lung adenocarcinoma is 53.3% through the mode, specificity is 82.9%, the average overall life cycle of patient groups with high risks of the lung adenocarcinoma is about 46 months, and the average overall life cycle of patient groups with low risks is about 94 months.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Plasma autoantibody biomarkers for diagnosis of lung cancer

An immune-proteomic screening of AAb responses using protein arrays has identified two panels of Aab (antigen / antibody complexes) that can potentially differentiate lung adenocarcinoma from smoker controls as well as CT positive benign lung disease. The resulting biomarkers appear to have high specificity so that high risk subjects with a positive CT screen and a positive serum test should get more invasive test such as needle biopsy for a timely cancer diagnosis, among other advantages.
Owner:ARIZONA STATE UNIVERSITY +1

Epitope of CD66C specific to lung adenocarcinoma and antibody recognizing the same

The present invention relates to epitope of CD66c specific to lung adenocarcinoma and antibody recognizing the same. The present invention relates to identifying epitope of CD66c specific to lung adenocarcinoma, antibody recognizing the same, cell lines producing the same and the applications in diagnosis, prevention and treatment of lung adenocarcinoma by using the same. The above CD66c epitope is specific to lung adenocarcinoma cells, and therefore the antibody or its fragment recognizing the epitope can be used in compositions to diagnose, treat and prevent lung adenocarcinoma cells.
Owner:KUMHO HT

ANXA3 gene or ANXA3 protein as biomarker of lung adenocarcinoma

The invention relates to the technical field of lung cancer gene detection, in particular to an ANXA3 gene or an ANXA3 protein as a biomarker of lung adenocarcinoma. Research findings, ANXA3 gene wasabnormally expressed in lung adenocarcinoma in both Xuanwei and non-Xuanwei areas. The expression of ANXA3 gene was lower or higher than normal level. ANXA3 gene or protein could be used as biomarkerof lung adenocarcinoma to diagnose lung adenocarcinoma, judge lymph node metastasis, assist TNM staging and prognosis. The invention provides an ANXA3 gene and an expression product thereof in preparation for prejudging whether lymph node metastasis of lung adenocarcinoma, The present invention provides a new diagnostic method for clinically diagnosing metastasis of lung adenocarcinoma and provides a new candidate drug for treating metastasis of lung adenocarcinoma. The present invention relates to a method for treating metastasis of lung adenocarcinoma and a pharmaceutical composition for treating lung adenocarcinoma.
Owner:FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV

HLJ1 gene expression

The human HLJ1 tumor suppressor gene is herein defined as regulated by promoter, enhancer, and silencer regions. HLJ1 promoter activity and gene expression are inversely correlated with metastatic ability. HLJ1 is highly expressed, and inducible, in cells with low metastatic ability and expressed to a lesser extent in highly metastatic cells. HLJ1 gene expression suppressed the growth of human lung adenocarcinoma cells in vitro, and inhibited tumor growth in vivo. It also impeded the motility of human adenocarcinoma cells and reduced the anchorage-independent growth capacity and invasiveness of metastatic lung adenocarcinoma cells. The degree to which human lung adenocarcinoma patients express HLJ1 predicts their survival prognosis and their probability of relapse.
Owner:NAT HEALTH RES INSTITUES

Anti-tumor quaternary ammonium salt derivative, preparation method and application thereof

The invention belongs to the technical field of medicine, discloses an anti-tumor quaternary ammonium salt derivative, a preparation method and application thereof, a series of anti-tumor derivativesprepared through corresponding chemical reactions, and the application of the derivatives in anti-tumor. The present invention shows that all synthetic diosgenin quaternary ammonium salt derivatives have obvious inhibitory effect on the proliferation of A549 lung cancer cells, H1975 lung adenocarcinoma cells, Aspc-1 metastatic pancreatic cancer cells and A431 skin squamous carcinoma cells, and theantitumor activity of most derivatives is better than that of diosgenin, and the antitumor activity of most derivatives is better than that of diosgenin on Ramos B lymphoma cells.
Owner:SOUTHWEST UNIVERSITY FOR NATIONALITIES +1

Lung adenocarcinoma miRNA marker

The invention discloses a miRNA marker, in particular to a lung adenocarcinoma miRNA marker which is miRNA-2116. The miRNA-2116 can be used for judging whether lung adenocarcinoma metastasis happens or predicting the metastasis risk of the lung adenocarcinoma. Test results show that the miRNA-2116 can effectively distinguish a lung adenocarcinoma metastasis sample from a non-metastasis sample. On the basis, the miRNA-2116 can also be used for preparing medicines for restraining lung adenocarcinoma metastasis or preventing lung adenocarcinoma metastasis. The lung adenocarcinoma miRNA marker provides a new diagnostic method for diagnosing lung adenocarcinoma metastasis at the molecular level clinically, and provides a new medicine target for gene therapy of lung adenocarcinoma metastasis.
Owner:昆明博奥三合医学检验实验室有限公司

Method for cultivating lymph-node autologous CIK (cytokine-induced killer) cells and application of lymph-node autologous CIK cells

The invention belongs to the field of biotechnology and microbial animal cell lines and particularly relates to a method for cultivating lymph-node autologous CIK (cytokine-induced killer) cells and application of the lymph-node autologous CIK cells. The CIK cells are obtained by in-vitro cultivation of isolated lymph node tissue obtained in surgery in patients with lung cancer and are compared with the CIK cells obtained from cultivation of isolated peripheral blood, biological characteristics of the CIK cells and cytotoxicity effect on pulmonary granule cancer cells are observed, the result shows that the isolated lymph node issue of the surgical patients can be completely used for cultivation of CIK, in-vitro tumor-cytotoxicity cells are powerful in activity, and the activity and cancer inhibition function are prior to the CIK cells of the peripheral blood. The CIK cells can be used for preparing pulmonary granule and cancer inhibition products and made into compounds with chemotherapy drugs as well as used for adoptive immunity and intervention for postoperative patients with lung cancers, and occurrence rate for recurrence and metastasis of the postoperative patients with the lung cancers is beneficially decreased.
Owner:SHANGHAI CHEST HOSPITAL

Chinese lung adenocarcinoma cell system and application thereof

The invention discloses a Chinese lung adenocarcinoma cell system CAFQ1 and application thereof. The preservation number of the cell system is CCTCC NO: C201774. The cell system has similar protein expression as that of primary tumor tissue, also has chromosome abnormal karyotype and has tumor properties of in-vitro tumor formation properties. By adopting the cell system, properties of lung adenocarcinoma tumor cells can be maintained after continuous in-vitro subculture, and the cell system is applicable to cell materials for researching and developing immunity treatment, diagnosis and medicines for lung adenocarcinoma. The cell system disclosed by the invention comprises ALK: Kras mutations, the two mutations can result normal pulmonary epithelial cell mutations and tumor formation and can promote tumor cell proliferation, therefore, the cell system can be used as powerful tool cells for studying target medicines with ALK; Kras as targets.
Owner:SHANGHAI CHEST HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products